Cytek Biosciences Narrows 2026 Revenue Guidance to $208M–$211M

Cytek Biosciences reported total revenue of $53.2 million for the third quarter of 2026, a 2% increase compared to the same period in 2025. The company achieved a GAAP gross margin of 59%, reflecting a 590 basis point improvement year-over-year. During the quarter, the company expanded its installed base by 140 units, reaching a total of 4,073 instruments. Management reiterated the midpoint of its full-year 2026 revenue guidance while narrowing the expected range to $208 million to $211 million. The company attributed the revenue growth to strong demand for high-end instruments and continued service expansion in the U.S. market.